News | November 07, 2025
Pfizer reports Q3 vaccine sales decline amid challenging US market conditions
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Inclacumab was generally well tolerated in THRIVE-131
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Subscribe To Our Newsletter & Stay Updated
